Sign up for our Oncology Central weekly news round-up

CheckMate 067: Phase III study of nivolumab alone or combined with ipilimumab vs. ipilimumab alone in patients with advanced melanoma

Clinical trials For clinicians

In this short video interview, expert Dr James Larkin of The Royal Marsden (UK) discusses the results of the pivotal CheckMate 067 trial, which were presented in the Plenary Session at the 2015 Annual Meeting of the American Society for Clinical Oncology.

The trial was the first to compare an immunotherapy combination of nivolumab and ipilimumab with other standards or care in advanced melanoma, and concluded that in the first line progression-free survival was significantly prolonged with the combination treatment. Watch now to hear more about the survival data, treatment side effects and the future of the trial.